After opening the day flat, share markets in India witnessed negative trading activity throughout the day and ended well below the dotted line. Sectoral indices ended the day in red, with stocks in the FMCG sector and stocks in the consumer durables sector leading the losses.

At the closing bell, the BSE Sensex stood lower by 139 points (down 0.4%) and the NSE Nifty closed down by 43 points (down 0.4%). The BSE Mid Cap index ended the day down by 0.6%, while the BSE Small Cap index ended the day down by 0.5%.

Asian stock markets finished in red. As of the most recent closing prices, the Hang Seng was down by 2.6% and the Shanghai Composite was down by 1.7%. The Nikkei 225 was down by 0.5%. Meanwhile, European markets too were trading in the red. The FTSE 100 was down by 0.5%, The DAX, was down by 0.6% while the CAC 40 was down by 1%.

The rupee was trading at Rs 71.74 against the US$ in the afternoon session. Oil prices were trading at US$ 77.22 at the time of writing.

In news from stocks in the pharma sector. Lupin share price was in focus today as the company said that the US Food and Drug Administration (USFDA) inspected its Tarapur facility and issued one observation for the same.

The USFDA, after the completion of the inspection of the facility, issued a single observation in form 483 to the company.

As per USFDA, observations are made in Form 483 when investigators feel that conditions or practices in the facility are such that products may become adulterated or render injuries to health.

The inspection focused on current good manufacturing practices compliance and also on the safety of Lupin’s Valsartan, Losartan and Irbesartan active pharmaceutical ingredients (commonly known as ‘Sartans’) in light of the safety alert issued by regulatory authorities on the NDMA (classified as a probable human carcinogen) impurity in Valsartan API (active pharmaceutical ingredient) supplied by some companies, it added.